ASTRAZENECA'S targeted cancer therapy Lynparza (olaparib) has been listed on the Pharmaceutical Benefits Scheme effective today, for the maintenance treatment of platinum-sensitive relapsed high-grade serious ovarian cancer (HGSOC) linked to the inherited BRCA gene mutation.
At the same time, germline BRCA mutation testing will also be reimbursed on the Medicare Benefits Schedule from 01 Feb 2017 for women with relapsed ovarian cancer after response to platinum chemotherapy, to assist them in determining their BRCA status.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 17